1197 related articles for article (PubMed ID: 16540552)
1. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
[TBL] [Abstract][Full Text] [Related]
2. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis.
Zink A; Thiele K; Huscher D; Listing J; Sieper J; Krause A; Gromnica-Ihle E; von Hinueber U; Wassenberg S; Genth E; Schneider M;
J Rheumatol; 2006 Jan; 33(1):86-90. PubMed ID: 16395755
[TBL] [Abstract][Full Text] [Related]
3. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
4. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
Kvamme MK; Lie E; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
[TBL] [Abstract][Full Text] [Related]
5. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
6. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
7. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
8. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
[TBL] [Abstract][Full Text] [Related]
10. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
Hallert E; Husberg M; Skogh T
Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
[TBL] [Abstract][Full Text] [Related]
11. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A
Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069
[TBL] [Abstract][Full Text] [Related]
12. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Kvamme MK; Kristiansen IS; Lie E; Kvien TK
J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
[TBL] [Abstract][Full Text] [Related]
13. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.
Boonen A; van den Heuvel R; van Tubergen A; Goossens M; Severens JL; van der Heijde D; van der Linden S
Ann Rheum Dis; 2005 Mar; 64(3):396-402. PubMed ID: 15271773
[TBL] [Abstract][Full Text] [Related]
14. The clinical application of etanercept in Chinese patients with rheumatic diseases.
Chou CT
Mod Rheumatol; 2006; 16(4):206-13. PubMed ID: 16906369
[TBL] [Abstract][Full Text] [Related]
15. [Methodologic aspects of public health economy].
Zink A
Z Rheumatol; 2004 Oct; 63(5):369-71. PubMed ID: 15517296
[No Abstract] [Full Text] [Related]
16. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.
Greenberg JD; Palmer JB; Li Y; Herrera V; Tsang Y; Liao M
J Rheumatol; 2016 Jan; 43(1):88-96. PubMed ID: 26628601
[TBL] [Abstract][Full Text] [Related]
17. The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis.
Campbell NKJ; Saadeldin K; De Vera MA
Curr Rheumatol Rep; 2017 Sep; 19(10):66. PubMed ID: 28921409
[TBL] [Abstract][Full Text] [Related]
18. Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres.
Zink A; Fischer-Betz R; Thiele K; Listing J; Huscher D; Gromnica-Ihle E; Specker C; Schneider M;
Lupus; 2004; 13(7):529-36. PubMed ID: 15352425
[TBL] [Abstract][Full Text] [Related]
19. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.
Zink A; Braun J; Listing J; Wollenhaupt J
J Rheumatol; 2000 Mar; 27(3):613-22. PubMed ID: 10743798
[TBL] [Abstract][Full Text] [Related]
20. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis.
Franke LC; Ament AJ; van de Laar MA; Boonen A; Severens JL
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S118-23. PubMed ID: 19822057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
